Storia in 2 fonti

Galderma Slumps After FDA Turns Down Botox Rival Relfydess

(Bloomberg) -- Galderma Group AG shares slumped the most in more than a year after the US Food and Drug Administration turned down the Swiss dermatology firm’s rival Botox treatment Relfydess.

Raccontata da

swissinfo.ch

healio.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

swissinfo.chStai leggendo2 g fa

Galderma Slumps After FDA Turns Down Botox Rival Relfydess

(Bloomberg) -- Galderma Group AG shares slumped the most in more than a year after the US Food and Drug Administration turned down the Swiss dermatology firm’s rival Botox treatment Relfydess.

originale

healio.com1 g fa

FDA rejects Galderma’s relabotulinumtoxinA for second time

The FDA declined to approve a biologics license application for Galderma’s relabotulinumtoxinA, citing manufacturing and testing concerns, according to a company press release. In its complete response letter, the FDA…

Leggi questa versione → originale

Galderma Slumps After FDA Turns Down Botox Rival Relfydess

Confronto fonti

Galderma Slumps After FDA Turns Down Botox Rival Relfydess

FDA rejects Galderma’s relabotulinumtoxinA for second time

Timeline cronologica

Galderma Slumps After FDA Turns Down Botox Rival Relfydess

FDA rejects Galderma’s relabotulinumtoxinA for second time

Galderma Slumps After FDA Turns Down Botox Rival Relfydess

Confronto fonti

Galderma Slumps After FDA Turns Down Botox Rival Relfydess

FDA rejects Galderma’s relabotulinumtoxinA for second time

Timeline cronologica

Galderma Slumps After FDA Turns Down Botox Rival Relfydess

FDA rejects Galderma’s relabotulinumtoxinA for second time